ACTA1 and scleroderma: Furthermore, rosiglitazone attenuated the activated phenotype of scleroderma fibroblasts, by suppressing α-SMA, type I collagen, and CTGF protein expression and by reducing the ability of these fibroblasts to contract collagen matrix [79].